UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  March 2, 2011 (March 1, 2011)
_______________
 

BIOCANCELL THERAPEUTICS INC.
 (Exact name of registrant as specified in its charter)
 
Delaware
333-156252
20-4630076
(State or other jurisdiction of incorporation)
Commission File Number
(IRS Employer Identification No.)

 
Beck Science Center, 8 Hartom St, Har Hotzvim, Jerusalem, Israel, 97775
(Address of principal executive offices and zip code)
 
Registrant’s telephone number, including area code: 972-2-548-6555


(Former name or former address, if change since last report)

 

 


Check the appropriate box below if the Form 8-K filing is to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
Item 5.02(b)
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officer
 
On March 1, 2011, Mr. Doron Nevo, who served as the Chairman of our Board of Directors, notified us that he is resigning his position as director immediately. He stated that his resignation is for personal reasons.

 
 

 

 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BIOCANCELL THERAPEUTICS, INC.
     
     
Dated: March 2, 2011
By:
/s/ Avraham Hampel
   
Avraham Hampel
   
Company Secretary